10x Genomics, Inc. (TXG)

NASDAQ: TXG · USD

$83.6

+5.61 (+7.2%)· Recorded snapshot

Market cap	10.9B
Revenue (ttm)	616.9M
Net income (ttm)	-75.1M
EPS (ttm)	-$0.59
Shares out	130.3M
Volume	4,427,862
Beta	1.99

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 616.9M
Net income (ttm): -75.1M
EPS (ttm): -$0.59
Market cap: 10.9B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-9.4

P25 n/aP50 n/aP75 n/a

ROIC-5.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All TXG indicators

Market & fundamental data

Available fields

227

Groups with data

Currency

USD

Showing 227 of 227 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001770787
Company name	10x Genomics, Inc.
Country	United States
Country code	US
CUSIP number	88025U109
Earnings date	2026-11-05
Earnings time	amc
Employees	1,178
Employees change	-128
Employees growth	-9.8%
Enterprise value	$10.4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2012
In index	RUSSELL2000
Industry	Medical Devices
IPO date	2019-09-12
Is primary listing	Yes
Is SPAC	No
ISIN number	US88025U1097
Last 10-K release date	2026-02-13
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$10.9B
Market cap category	Large-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$83.63
Price currency	USD
Sector	Healthcare
SIC code	3826
Stock price date	2026-10-28
Symbol	TXG
U.S. state	California
Website	https://www.10xgenomics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	574.42x
Earnings yield	-0.7%
EV/FCF	85.7x
EV/Sales	16.87x
FCF / EV yield	1.17%
FCF yield	1.12%
Forward EV/Sales	16.09x
Forward P/S	16.83x
Industry forward P/E	19.74x
Industry P/E	39.16x
P/(FCF - SBC) ratio	479.43x
P/(OCF - SBC) ratio	383.88x
P/B ratio	12.31x
P/FCF ratio	89.6x
P/OCF ratio	85.62x
P/S ratio	17.64x
Price / tangible book value	14.36x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-13.16%
EBITDA margin	-6.68%
FCF margin	19.68%
Gross margin	70.11%
Operating margin	-13.16%
Pretax margin	-12.14%
Profit margin	-12.18%
Profit per employee	$-63,773
Revenue per employee	$523,694
ROA	-5.05%
ROA (5Y)	-9.03%
ROCE	-8.91%
ROE	-9.4%
ROE (5Y)	-18.37%
ROIC	-5.75%
SBC / revenue	16.01%
Tax / revenue	0.04%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	2
FCF growth	113.51%
FCF growth (Q)	-4.61%
FCF growth (QoQ)	-37.26%
Gross profit growth	-3.36%
Gross profit growth (Q)	-10.06%
Gross profit growth 3Y	1.11%
Gross profit growth 5Y	4.3%
Net income growth years	2
OCF growth	89.82%
OCF growth (Q)	-4.15%
OCF growth (QoQ)	-35.02%
Revenue growth	-4.28%
Revenue growth (Q)	-12.65%
Revenue growth (QoQ)	0.13%
Revenue growth 3Y	2.77%
Revenue growth 5Y	8.74%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-5.6M
Depreciation and amortization	$40M
EBIT	$-81.2M
EBITDA	$-41.2M
EPS	$-0.59
FCF per share	$0.93
Financing cash flow	$-2.5M
Free cash flow	$121.4M
Free cash flow minus SBC	$22.7M
Gross profit	$432.5M
Income taxes	$235,000
Investing cash flow	$-19.7M
Net cash flow	$104.8M
Net income	$-75.1M
Operating cash flow minus SBC	$28.3M
Operating income	$-81.2M
Revenue	$616.9M
Stock-based compensation	$98.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.75
Book value per share	$6.34
Debt / equity	0.1
Debt / FCF	0.65
Goodwill	$6.9M
Long-term assets	$355.4M
Long-term liabilities	$86M
Net cash (debt)	$473.2M
Net cash / market cap	4.35%
Net cash growth	31.27%
Net debt / equity	-0.57
Net debt / FCF	-3.9
Piotroski F-Score	3
Property, plant and equipment	$272M
Shareholders' equity	$825.5M
Tangible book value	$757.5M
Tangible book value per share	$5.81
Total assets	$1B
Total cash	$552M
Total debt	$78.8M
Total liabilities	$204.5M
WACC	15.09%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.61
Current assets	$674.7M
Current liabilities	$118.5M
Current ratio	5.69
Inventory turnover	3.03
Net working capital	$16.1M
Quick ratio	5.09
Working capital	$556.2M
Working capital turnover	1.12

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-4.39%
Dividend yield	0%
Shareholder yield	-4.39%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$46.67
1D price change	7.19%
1M price change	-2.44%
1M total return	-2.44%
1W price change	17.02%
1W total return	17.02%
1Y price change	515.31%
1Y return CAGR	516.07%
1Y total return	515.31%
20-day SMA	$77.49
200-day SMA	$40.02
3M price change	82.1%
3M total return	82.1%
3Y price change	129.66%
3Y return CAGR	31.93%
3Y total return	129.66%
50-day SMA	$73.66
50-day SMA vs 200-day SMA	50over200
52-week high	$102.81
52-week high date	2026-10-06
52-week low	$12.34
52-week low date	2025-10-30
5Y price change	-47.39%
5Y return CAGR	-12.06%
5Y total return	-47.39%
6M price change	275.31%
6M total return	275.31%
All-time high	$208.99
All-time high date	2021-06-29
All-time low	$6.78
All-time low date	2025-04-07
Average true range (ATR)	$6.52
Average volume	4M
Beta (1Y)	1.03
Beta (2Y)	1.53
Beta (5Y)	1.99
Change from 52-week high	-18.66%
Change from 52-week low	577.72%
Change from all-time high	-59.99%
Change from all-time low	1,133.33%
Change from open	6.37%
Day's gap	0.77%
Dollar volume	$370.3M
High price	$87.55
Low price	$78.62
Monthly RSI	76.43
Open price	$78.62
Position in 52-week range	56.1%
Premarket change	0.94%
Premarket close	$78.02
Premarket price	$78.75
Premarket volume	9.9K
Previous close	$78.02
Price vs 150-day SMA	79.19%
Price vs 20-day SMA	7.91%
Price vs 200-day SMA	108.93%
Price vs 50-day SMA	13.52%
Relative volume	1.11
Return from IPO open	54.65%
Return from IPO price	114.13%
RSI	59.46
Sharpe ratio	2.76
Sharpe ratio (3Y)	0.65
Sharpe ratio (5Y)	0.11
Sortino ratio	4.95
Sortino ratio (3Y)	1.06
Sortino ratio (5Y)	0.25
Volume	4.4M
Weekly RSI	68.99
YTD price change	412.69%
YTD total return	412.69%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	118.2M
Float percentage	90.72%
Shares change (QoQ)	1.32%
Shares change (YoY)	4.39%
Shares held by insiders	7.79%
Shares held by institutions	101.4%
Shares outstanding	130.3M
Short % of float	13.01%
Short % of shares	11.8%
Short ratio	5.2 days

Deeper analysis on TXG

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TXG report

Is a complete TXG research report available?

No complete published report is available for 10x Genomics, Inc. (TXG) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

10x Genomics, Inc. (TXG)

Price

Financial snapshot

Fair-value bridge

Latest news · TXG

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TXG indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TXG

Frequently asked questions